Drug intelligence / Profile preview

Eritromax

Development stage: Phase 1
Lead developer: Blau Farmacêutica
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

Eritromax is a recombinant human erythropoietin (rHuEPO) product, specifically Epoetin Alfa, marketed by Blau Farmacêutica. It functions as an erythropoiesis-stimulating agent, primarily indicated for the treatment of anemia, particularly secondary anemia associated with chronic kidney disease. Its mechanism involves binding to and activating the erythropoietin receptor, thereby promoting the proliferation and differentiation of erythroid progenitor cells in the bone marrow to increase red blood cell production.

Brand names: Eritromax
Other names: Recombinant Human Erythropoietin InjectionHuman Erythropoietin InjectionErythropoietinr-HuEPOEpoetin alfa

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on Eritromax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eritromax.

Explore the full profile